TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-06-27 am EDT
3776.00 JPY   +1.86%
06:02aResults from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
BU
06/24Takeda Pharmaceutical to Absorb Businesses From Unit Nihon Pharmaceutical
MT
06/22Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société TAKEDA PHARMACEUTICAL COMPANY LIMITED
06:02aResults from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficienc..
BU
06/22Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation..
BU
06/10Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Th..
AQ
06/10TAKEDA PHARMACEUTICAL : Notice Concerning Disposal of Treasury Shares under the Long-Term ..
PU
06/09Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Th..
BU
06/07Takeda Canada applauds Quebec's new Rare Disease Policy
AQ
06/02Takeda Pharmaceutical Company Limited - Notice Concerning Withdrawal of Shelf Registrat..
AQ
05/31Takeda and Moderna Announce Plans to Transfer Marketing Authorization for SpikevaxTM CO..
AQ
05/31Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
BU
05/31TAKEDA PHARMACEUTICAL : Current Report by Foreign Issuer (Form 6-K)
PU
05/31TAKEDA PHARMACEUTICAL : Current Report by Foreign Issuer (Form 6-K)
PU
05/31Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax&trad..
BU
05/27TAKEDA PHARMACEUTICAL : and Seagen to Highlight ADCETRIS Combination Data
PU
05/26Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Signifi..
BU
05/11Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
BU
04/28CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient ..
AQ
04/27Takeda Recognized as 2022 ISPE Facility of the Year Awards Winner in Two Categories
AQ
04/26Takeda Holds Fourth Quarter and Full-Year FY2021 Earnings Call on May 11
AQ
04/26Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
BU
04/25TAKEDA PHARMACEUTICAL : Holds Fourth Quarter and Full-Year FY2021 Earnings Call on May 1
PU
04/22Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY&trade..
BU
04/19Takeda's TAKHZYRO (lanadelumab-flyo) Prefilled Syringe Now Available for People With He..
AQ
04/18Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immuni..
BU
04/18Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With H..
BU
04/13Takeda Announces Completion of Acquisition of Own Shares
BU
04/12Takeda's TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Childre..
BU
04/09Exclusive Speaker Interview with Ester Lovsin Barle Ahead of the 6th Annual Highly Pote..
AQ
04/05Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award W..
BU
04/04Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
AQ
04/01Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
BU
03/29Takeda's TAKHZYRO (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks..
AQ
03/28Takeda's TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attack..
BU
03/01Takeda - Interim Phase 4 Data Support TAKHZYRO (lanadelumab) as an Effective Treatment ..
AQ
02/28Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduc..
BU
02/21Takeda - Alofisel(darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Rea..
AQ
02/18Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Rea..
BU
02/16Ipsen - Cabometyx in combination with Opdivo demonstrated continued survival and qualit..
AQ
02/10Takeda's Ramona Sequeira Becomes Board Chair of PhRMA
AQ
02/10Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of TAKHZYRO (lanad..
AQ
02/04Takeda Pharmaceutical - Notice of the Revised Forecast of Consolidated Financials for F..
AQ
02/03Takeda Pharmaceutical Company Limited - Notice of the Revised Forecast of Consolidated ..
AQ
02/03Takeda Announces Strategic Leadership Changes to Help Drive Continued Growth and Compet..
AQ
02/03TAKEDA PHARMACEUTICAL : Announces Strategic Leadership Changes
PU
02/03Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Refle..
BU
02/03TAKEDA PHARMACEUTICAL : Summary of Financial Statements for the Nine-months Period Ended D..
PU
02/03TAKEDA PHARMACEUTICAL : Provides Update on Status of Acquisition of Own Shares
PU
02/03TAKEDA PHARMACEUTICAL : Notice of the Revised Forecast of Consolidated Financials for FY20..
PU
02/03TAKEDA PHARMACEUTICAL COMPANY LIMITE : Notice of the Revised Forecast of Consolidated Fina..
EQ
02/01FDA Approves Prophylactic Treatment with VONVENDI for Adult Patients Living with Sever..
AQ
01/31FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)..
BU
01/27TAKEDA PHARMACEUTICAL : Selects Four New Partners for Annual Global Corporate Social Respo..
PU
01/24Takeda to Hold Third Quarter FY2021 Earnings Conference Call
AQ
01/21TAKEDA PHARMACEUTICAL : to Hold Third Quarter FY2021 Earnings Conference Call
PU
01/19Takeda Named Global Top Employer for Fifth Consecutive Year
BU
01/12Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40..
AQ
01/11Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta T Cell Engager ..
AQ
01/10PRESENTATION : Better health for people, Brighter future for the world
PU
01/10TAKEDA PHARMACEUTICAL : Emphasizes Strategy for Delivering Sustainable Growth Over Next De..
PU
01/10Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40..
BU
01/10Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ..
BU
01/05Takeda to Present at The 40th Annual J.P. Morgan Healthcare Conference
AQ
01/05TAKEDA PHARMACEUTICAL : to Present at The 40th Annual JP Morgan Healthcare Conference
PU
2021TAKEDA PHARMACEUTICAL : Moderna and the Japanese Government Collaborate to Increase Modern..
PU
2021Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
BU
2021Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Ch..
AQ
2021Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Ch..
BU
2021Takeda Pharmaceutical - Maintaining trust in science is crucial to public health. Here'..
AQ
2021GENERAL ANNOUNCEMENT : :Takeda Submits New Drug Application for Novavax COVID-19 Vaccine C..
PU
2021TAKEDA PHARMACEUTICAL : Submits New Drug Application for Novavax' COVID-19 Vaccine Candida..
PU
2021URGENT : Japan gov't panel OKs Moderna's COVID-19 vaccine as booster
AQ
2021Takeda Drives Continued Scientific Leadership through Real-World Evidence in Rare Hemat..
AQ
2021GENERAL ANNOUNCEMENT : :Share Repurchase Report (From November 1, 2021 to November 30, 202..
PU
2021 Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hema..
BU
2021Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENC..
AQ
2021Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENC..
BU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on TAKEDA PHARMACEUTICAL COMPANY LIMITED